Drugs / KRRO-110
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Filed | Other | — | alpha 1-antitrypsin deficiency | 2024-11-04 | “Korro submitted a regulatory filing with the Australian Bellberry Human Research Ethics Committee (HREC) to initiate a Phase 1/2 clinical study for KRRO-110 in AATD.” korrobio.com ↗ “today announced a submission to the Bellberry HREC for a Phase 1/2 clinical study of KRRO-110 for AATD.” korrobio.com ↗ |
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06677307 | Jan → Oct 2025 | alpha 1-antitrypsin deficiency | Korro Bio, Inc. | Terminated | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 8
| Date | Issuer | Release |
|---|---|---|
| 2025-11-12 | Frequency Therapeutics | Results Korro Reports Third Quarter Financial Results, Provides Updates on KRRO-110 in Alpha-1 Antitrypsin Deficiency and Additional Pipeline Programs korrobio.com ↗
Today, we announced that KRRO-110 generated functional M-AAT protein in AATD patients. |
| 2025-07-21 | Frequency Therapeutics | Regulatory Korro Receives European Medicines Agency Orphan Drug Designation for KRRO-110 korrobio.com ↗
Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, announced today that it has been granted orphan drug designation by the European Medicines Agency (EMA) Committee, who adopted a positive opinion on KRRO-110, Korro’s investigational medicine for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). |
| 2025-03-14 | Frequency Therapeutics | Regulatory KRRO-110 Receives Orphan Drug Designation from U.S. FDA for Alpha-1 Antitrypsin Deficiency korrobio.com ↗
Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the investigational medicine KRRO-110 for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). |
| 2024-11-21 | Frequency Therapeutics | Regulatory Korro Receives Australian HREC Approval and CTN Clearance to Initiate Phase 1/2a Clinical Study (REWRITE) of KRRO-110 for Alpha-1 Antitrypsin Deficiency korrobio.com ↗
Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today announced that it has received approval from the Australian Bellberry Human Research Ethics Committee (HREC) and clearance from the Australian Therapeutic Goods Administration (TGA) to initiate a Phase 1/2a clinical study of KRRO-110 for Alpha-1 Antitrypsin Deficiency (AATD). |
| 2024-11-12 | Frequency Therapeutics | Regulatory Korro Reports Third Quarter 2024 Financial Results and Provides Business Updates korrobio.com ↗ |
| 2024-11-04 | Frequency Therapeutics | Regulatory Korro Announces Regulatory Filing for Initiation of KRRO-110 First-In-Human Study and Formation of Clinical Advisory Board korrobio.com ↗
Regulatory filing of Phase 1/2 clinical study for Alpha-1 Antitrypsin Deficiency (AATD) submitted to Australian Bellberry Human Research Ethics Committee (HREC) |
| 2024-05-20 | Frequency Therapeutics | Results Korro Presents Additional Preclinical Data for KRRO-110 at the American Thoracic Society 2024 International Conference korrobio.com ↗
New data for KRRO-110 shows approximately 60% editing efficiency and greater than 60µM total AAT (45µM M-AAT) protein at week 13, while previous data showed efficacy up to week 9. |
| 2024-01-18 | Frequency Therapeutics | Results Korro Bio Highlights Data for its Lead Program in Alpha-1 Antitrypsin Deficiency (AATD) and Progress Across its RNA Editing Portfolio korrobio.com ↗
“KRRO-110 data showed the highest levels of corrected protein in a human transgenic PiZ mouse model, supporting a potentially best-in-class therapeutic for AATD patients,” |
All press releases naming this drug 9 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KRRO-110 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06677307 ↗ |
| Modality | Oligonucleotide (other) | “KRRO-110 is an RNA editing oligonucleotide” NCT06677307 ↗ |
| Route | Intravenous | “administered by intravenous (IV) infusion” NCT06677307 ↗ |